France Legalizes CBD Cannabis Derived Products with THC below 0.3%

Jan.06.2023
France Legalizes CBD Cannabis Derived Products with THC below 0.3%
France legalizes sales of CBD-derived products with THC up to 0.3% but still bans sales of unprocessed cannabis flowers.

According to French media outlet RFI, on December 30th, 2021, the French government legalized the sale of cannabis-derived products containing CBD, with a THC content of no more than 0.3%, one year after lifting the ban on CBD. However, cannabis enthusiasts and those who favor Delta-8 (D8) may be disappointed to learn that the government still prohibits the sale of cannabis flowers, citing their supposed psychoactive effects.


However, a high court in France overturned the ban, ruling that CBD has not been proven harmful and that there are other legal uses for the plant besides smoking.


On December 29th, the French State Council (an institution that provides legislative proposals to the government and serves as the highest court) ruled that a comprehensive and absolute ban on the sale of raw forms of CBD was "disproportionate." They also found no conclusive evidence of harm from CBD. If any evidence exists, it is to the contrary.


The harmful effects of other molecules present in cannabis flowers and leaves, particularly CBD, have not yet been determined," the committee said. The committee added that there is evidence to suggest that CBD has "relaxing properties and anti-seizure effects, but no psychoactive effects, nor does it cause dependency.


In other words, the court ruled that marijuana should not automatically be classified as a psychoactive drug, as this is far from the truth. Additionally, it can be used not only for smoking, but also for making tea or infused oil. Other factors to consider are homemade tinctures or vaporizing the flowers.


Concerns about distinguishing between different types of cannabis.


Despite the recent court ruling allowing for cannabis cultivation, concerns have been raised about the government's plans to distinguish between cannabis and its highly potent derivative, tetrahydrocannabinol (THC), which is nearly indistinguishable to the naked eye. The State Council maintains that THC levels "can be controlled through rapid testing.


In November 2020, the European Court ruled that a ban on CBD that is legal in other European countries is illegal in France, based on the principle of free movement of goods.


The highest court of justice in France ruled in June of last year that any CBD produced legally in the European Union can be sold legally in France.


According to the French Professional Cannabis Association (SPC), as reported by RFI, there are now approximately 2,000 CBD shops operating in France. The industry's annual turnover is estimated to be around €500 million, or $534.1 million USD. More than half of these sales come solely from flowers.


Experts in the country have stated that the latest court ruling provides a green light for the economically sustainable cannabis industry that can withstand the test of time.


According to a report by Hemp Today, the French Senate committee has stated that legalizing cannabis in France could generate an annual revenue of 1.5 euros (160 billion USD) to 2.5 billion euros (260 billion USD) and create between 18,000-20,000 job opportunities.


The French extractive trade group, UIVEC, estimates that the grey market for CBD in France will be worth around 200 million euros ($214 million) by 2021, and is expected to reach about 300 million euros ($321 million) this year. UIVEC also estimates that by 2022, approximately 300-500 hectares of cannabis will be grown for hemp flower CBD production.


As legislation moves forward, these regulations are expected to be implemented in early 2023. The government is expected to announce that marijuana is in compliance with the European Union's common agriculture policy, develop an industry strategy, and create specific regulations.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Azerbaijan's sweeping e-cigarette ban has raised concerns over enforcement errors and the emergence of illicit sales, while neighboring Armenia is tightening technical rules and preparing higher excise taxes. Georgia, meanwhile, has resisted calls for broader vape restrictions and introduced preferential taxes for some domestically produced cigarettes. The divergent approaches across the South Caucasus highlight a regional policy dilemma: how to curb nicotine use and protect public health without encouraging black markets or creating unintended economic consequences for businesses and consumers.
Nov.03